BioPharma Credit PLC
BioPharma Credit PLC
Your view on BOPCF
Overview
What the company does, where it operates, and who runs it.
About BioPharma Credit PLC
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Pedro Gonzalez de Cosio
- Headquarters
- 51 New North Road, Exeter, GB
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Pedro Gonzalez de Cosio
- Headquarters
- 51 New North Road, Exeter, GB
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in Exeter, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioPharma Credit PLC, and the rating behind it. BOPCF last traded at $0.88, 8.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioPharma Credit PLC. Starting points for BioPharma Credit PLC: P/E 8.5, EPS $0.12, beta 0.19 — an Asset Management name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioPharma Credit PLC. BioPharma Credit PLC does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioPharma Credit PLC. Trailing twelve-month EPS for BioPharma Credit PLC stands at $0.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioPharma Credit PLC. BioPharma Credit PLC has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioPharma Credit PLC valued side by side against its closest peers. BioPharma Credit PLC is measured against Asset Management peers within the Financial Services sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioPharma Credit PLC, and how their positions are changing. At a $996.4M market value, institutional positions materially move BioPharma Credit PLC's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioPharma Credit PLC executives and directors. Shares of BioPharma Credit PLC have traded between $0.78 and $0.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioPharma Credit PLC. BioPharma Credit PLC is a $996.4M Financial Services company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioPharma Credit PLC. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioPharma Credit PLC. Coverage tracks BioPharma Credit PLC within Asset Management (Financial Services). Press releases and market coverage, newest first.